Cargando…

Homocitrullination of lysine residues mediated by myeloid-derived suppressor cells in the tumor environment is a target for cancer immunotherapy

BACKGROUND: Homocitrullination is the post-translational modification of lysine that is recognized by T cells. METHODS: This study identified homocitrullinated peptides from aldolase, enolase, cytokeratin and binding immunoglobulin protein and used human leukocyte antigen (HLA) transgenic mice to as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cook, Katherine W, Xue, Wei, Symonds, Peter, Daniels, Ian, Gijon, Mohamed, Boocock, David, Coveney, Clare, Miles, Amanda K, Shah, Sabaria, Atabani, Suha, Choudhury, Ruhul H, Vaghela, Poonam, Weston, Daisy, Metheringham, Rachael L, Brentville, Victoria A, Durrant, Lindy G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320257/ https://www.ncbi.nlm.nih.gov/pubmed/34321274 http://dx.doi.org/10.1136/jitc-2020-001910

Ejemplares similares

Vaccine Can Induce CD4-Mediated Responses to Homocitrullinated Peptides via Multiple HLA-Types and Confer Anti-Tumor Immunity
por: Cook, Katherine, et al.
Publicado: (2022)

Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses
por: Brentville, Victoria A, et al.
Publicado: (2020)

T cell repertoire to citrullinated self-peptides in healthy humans is not confined to the HLA-DR SE alleles; Targeting of citrullinated self-peptides presented by HLA-DP4 for tumour therapy
por: Brentville, Victoria A, et al.
Publicado: (2019)

Vaccination with post-translational modified, homocitrullinated peptides induces CD8 T-cell responses that mediate antitumor immunity
por: Shah, Sabaria, et al.
Publicado: (2023)

PAD-2-mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy
por: Choudhury, Ruhul H, et al.
Publicado: (2022)

Citrullinated glucose-regulated protein 78 is a candidate target for melanoma immunotherapy
por: Brentville, Victoria Anne, et al.
Publicado: (2022)

Citrullinated α-enolase is an effective target for anti-cancer immunity
por: Cook, Katherine, et al.
Publicado: (2017)

Citrullinated Epitopes Identified on Tumour MHC Class II by Peptide Elution Stimulate Both Regulatory and Th1 Responses and Require Careful Selection for Optimal Anti-Tumour Responses
por: Symonds, Peter, et al.
Publicado: (2021)

High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment
por: Brentville, Victoria A., et al.
Publicado: (2012)

SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
por: Xue, Wei, et al.
Publicado: (2016)

SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade
por: Xue, Wei, et al.
Publicado: (2016)

Cancer Vaccines, Adjuvants, and Delivery Systems
por: Paston, Samantha J., et al.
Publicado: (2021)

A Novel HAGE/WT1-ImmunoBody(®) Vaccine Combination Enhances Anti-Tumour Responses When Compared to Either Vaccine Alone
por: Almshayakhchi, Rukaia, et al.
Publicado: (2021)

GC-MS Discrimination of Citrulline from Ornithine and Homocitrulline from Lysine by Chemical Derivatization: Evidence of Formation of N(5)-Carboxy-ornithine and N(6)-Carboxy-lysine
por: Baskal, Svetlana, et al.
Publicado: (2021)

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial
por: Patel, Poulam M., et al.
Publicado: (2018)

Current Strategies to Enhance Anti-Tumour Immunity
por: Cook, Katherine W., et al.
Publicado: (2018)

Quantification of the Effect of Citrulline and Homocitrulline Residues on the Collision-Induced Fragmentation of Peptides
por: Steckel, Arnold, et al.
Publicado: (2020)

High expression level of homocitrulline is correlated with seborrheic keratosis and skin aging()
por: Chen, Juping, et al.
Publicado: (2023)

Comparison of homocitrulline and carbamylated albumin as biomarkers of carbamylation reactions in hemodialyzed patients
por: Lenglet, Aurelie, et al.
Publicado: (2023)

Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer
por: Gadwa, Jacob, et al.
Publicado: (2021)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
por: Tannir, Nizar M, et al.
Publicado: (2022)

Expression of citrulline and homocitrulline residues in the lungs of non-smokers and smokers: implications for autoimmunity in rheumatoid arthritis
por: Lugli, Elena B, et al.
Publicado: (2015)

Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis
por: Knitz, Michael W, et al.
Publicado: (2021)

Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer
por: Coveney, Clare, et al.
Publicado: (2015)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
por: Vitanza, Nicholas, et al.
Publicado: (2020)

IMMU-10. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL TREG DEPLETION IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RELAPSED HIGH-GRADE GLIOMAS
por: Eyrich, Matthias, et al.
Publicado: (2020)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

IMMU-23. A NOVEL MASS CYTOMETRY-BASED MULTI-PARAMETER CHARACTERIZATION OF NEOANTIGEN-REACTIVE CD8+ T-CELLS IN PATIENTS PARTICIPATING IN PNOC007 H3.3K27M PEPTIDE VACCINE CLINICAL TRIAL
por: Taitt, Jared, et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

IMMU-21. INVESTIGATION OF WHITE BLOOD CELL CHARACTERISTICS IN CSF SAMPLES AT PEDIATRIC BRAIN TUMOR DIAGNOSIS
por: Greer, Hunter, et al.
Publicado: (2020)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS
por: de Billy, Emmanuel, et al.
Publicado: (2020)

IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
por: Mueller, Sabine, et al.
Publicado: (2020)

IMMU-22. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Madrid, Andres Morales La, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tv8s88doamciefg1puehfuhalg